author Emily J. Thompson, Senior investment analyst
sauce: Benzinga
Update date: 31 minutes ago
0minutes
sauce: Benzinga
- Partnership established: Gaxos.ai has signed an agreement with Byteplus to secure preferential pricing and deep discounts on ByteDance’s advanced video generation models. This will accelerate the deployment of AI capabilities on the Art-Gen platform and enhance the ease and professionalism of content creation.
- Accelerating market penetration: This partnership will enable Gaxos to rapidly penetrate the multi-billion dollar global creator economy by incorporating cutting-edge AI video tools, reducing infrastructure costs and increasing scalability, thereby strengthening the company’s competitive advantage.
- AWS support and capital plans: Gaxos collaborates with AWS partner Caylent to develop a real-time sales platform featuring live call transcription, automated coaching insights, and post-call analytics to further strengthen market competitiveness.
- Launch of funding initiative: Gaxos recently launched a $3 million public market offering through HC Wainwright. This is expected to provide additional financial support for the company’s future growth.
Trade with backtested 70% accuracy
sign up
Analyst’s view GXAI
About GXAI
Gaxos.ai Inc. is a technology-based company. We are focused on addressing health, longevity, and entertainment through artificial intelligence (AI) solutions. The company’s services include health, wellness, and gaming. Its flagship product is a gaming platform called Gaxos (Gaxos Gaming), created to develop, design, acquire, and manage traditional games and combine these games with unconventional game mechanics. These include the ability for gamers and developers to leverage artificial intelligence to create and design in-game features, and to mint in-game features such as skins, characters, weapons, gear, levels, and virtual lands in the form of non-fungible tokens (NFTs). This gives users more control over in-game assets. The company’s Gaxos Health integrates AI-driven insights with personal biometric data and health goals to create personalized health strategies for web and app-based users.
About the author
Emily J. Thompson
Emily J. Thompson is a Certified Financial Analyst (CFA) with 12 years of experience in investment research and a cum laude graduate of the Wharton School. Specializing in industrial and technology stocks, we provide in-depth analysis of Intellectia’s earnings and market overview reports.
Gaxos.ai completes partnership with Byteplus on AI video tools
31 minutes agoBenzinga
- Partnership established: Gaxos.ai has signed an agreement with Byteplus to secure preferential pricing and deep discounts on ByteDance’s advanced video generation models. This will accelerate the deployment of AI capabilities on the Art-Gen platform and enhance the ease and professionalism of content creation.
- Accelerating market penetration: This partnership will enable Gaxos to rapidly penetrate the multi-billion dollar global creator economy by incorporating cutting-edge AI video tools, reducing infrastructure costs and increasing scalability, thereby strengthening the company’s competitive advantage.
- AWS support and capital plans: Gaxos collaborates with AWS partner Caylent to develop a real-time sales platform featuring live call transcription, automated coaching insights, and post-call analytics to further strengthen market competitiveness.
- Launch of funding initiative: Gaxos recently launched a $3 million public market offering through HC Wainwright. This is expected to provide additional financial support for the company’s future growth.
Gaxos.AI partners with Amazon Web Services on AI sales platform
February 3, 2026Stock Twits
- Rapid increase in inventory: Gaxos.AI Inc. (GXAI) stock soared more than 45% on Tuesday following the announcement of a partnership with Amazon Web Services (AWS), demonstrating strong market optimism and investor confidence in the company’s growth potential.
- Platform development support: AWS helps develop a real-time AI sales platform called Gaxos Labs. The platform incorporates live call transcription, automated coaching intelligence, and post-call analytics and aims to improve sales team performance through enterprise-scale implementation.
- Infrastructure benefits: Built entirely on AWS-native infrastructure, Gaxos Labs helps you integrate and prototype core platform functionality while ensuring rapid scalability, low latency, and commercial readiness, reducing dependence on external providers for operational efficiency.
- positive market reaction: On Stocktwits, retail sentiment around GXAI shifted from “bearish” to “very bullish,” message volume increased from “high” to “very high,” and the stock price rose further, reflecting investors’ enthusiastic response to the partnership with Amazon.
Gaxos.ai stock soars after AWS funding announcement
February 3, 2026Benzinga
- AWS Funding Support: Gaxos.ai announced that Amazon Web Services (AWS) will fund the preliminary development of its AI sales coaching platform. This is a major validation event that is expected to significantly increase market confidence and enhance the company’s commercial opportunities.
- Strong stock price performance: Following this announcement, Gaxos.ai’s stock price surged 53.90% and is currently trading at $2.17, reflecting strong investor optimism about the company’s future, with approximately 164 million shares traded today, indicating high market activity.
- Starting a financing plan: Gaxos.ai also announced a $3 million public offering through HC Wainwright. This earns you a 3% commission and provides additional funding to accelerate product development and strategic initiatives.
- Market volatility analysis: Despite the significant price increase, Gaxos.ai’s stock price is still 21% below its 52-week high, indicating cautious market sentiment about the company’s long-term growth potential, while also presenting a potential buying opportunity for investors.
U.S. stocks rise in morning trading, Dow up more than 100 points
January 26, 2026Benzinga
- Strong Dow performance: Reflecting the market’s optimistic sentiment on economic recovery, the Dow Jones index rose more than 100 points on Monday, rising 0.33% to 49,259.65.
- Earnings mistakes in the steel sector: Steel Dynamics Inc. reported fourth-quarter earnings of $1.82 per share, below consensus estimates of $1.95, and revenue of $4.414 billion, below expectations of $4.575 billion, illustrating challenges within the industry.
- Oil and gas inventories soar: Battalion Oil Corporation shares soared 379% to $6.13 after switching gas processing partners and increasing production, while Brand Engagement Network Inc.’s stock soared 196% to $48.79 after announcing a strategic partnership, highlighting strong investor interest.
- Improving economic data: U.S. durable goods orders increased 5.3% month-on-month in November, exceeding market expectations for a 3.7% increase after a revised 2.1% decline in October, suggesting a gradual recovery in economic activity.
Gaxos.AI (GXAI) stock falls after soaring price on introduction of new AI platform
August 20, 2025Benzinga
-
stock price performance: Gaxos.AI Inc (GXAI) stock price is experiencing a pullback after a significant rally following the announcement of its new AI platform, Art-Gen.AI.
-
Art-Gen.AI Overview: The Art-Gen.AI platform is designed for image and video creation by leveraging advanced AI models from Google and Stability AI, allowing users to generate high-quality content from text prompts and reference images.
-
Main features: Notable features include one-click upscaling of low-resolution images, dynamic video creation from still photos, and a variety of style presets with a subscription-based model aimed at gaining market share in the generative AI space.
-
market reaction:The stock price decline suggests investors are reevaluating the initial excitement around the product launch while digesting the impact of Gaxos.AI’s entry into the rapidly growing generative AI market.
Rocket Pharmaceuticals’ stock price soared more than 15%. Check out 20 stocks whose prices move in pre-market trading
August 20, 2025Benzinga
-
Rocket Pharmaceutical’s latest information: Shares of Rocket Pharmaceuticals rose 15.8% in pre-market trading after the FDA lifted the clinical hold on a Phase 2 clinical trial of RP-A501 to treat Danon’s disease.
-
Pre-market stock price movements: Several stocks experienced big changes in pre-market trading, including Novavay Pharmaceuticals, which rose 64.2%, and James Hardy Industries, which fell 27% after disappointing quarterly results.
-
Notable risers:Other notable gainers include Propanc Biopharma (up 37.8%) and ScanTech AI Systems (up 36.4%), both benefiting from positive investment and partnership announcements.
-
big loser: Stocks that fell include Cytosorbents Corporation (down 25.7%) due to regulatory updates and La-Z-Boy Incorporated (down 22.2%), which reported weaker-than-expected financial results.
